Image credit: Canva
Esophageal cancers can be difficult to treat and commonly recur despite current intervention options like chemoradiation and surgery. Consequently, researchers are looking for more therapy options. A clinical trial led by David S. Schrump, M.D., M.B.A., FACS, Chief and Senior Investigator in the Thoracic Surgery Branch, is researching a combination vaccine and drug therapy for esophageal cancers.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Deneise Francis, R.N., at (240) 328-2693 or deneise.francis@nih.gov.
Clinicaltrials.gov identifier: NCT05898828
NCI Protocol ID: IRB001544
Official Title: Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.